Enstilar is a topical treatment for plaque psoriasis aged 12 years and older, owned by Leo Pharma As. The drug's active ingredients are Betamethasone Dipropionate and Calcipotriene. Enstilar was first authorized for market use on 16 October, 2015, and is available in aerosol, foam; topical dosage forms. Enstilar holds 10 drug patents in total.
The generic version of Enstilar may become available after 10 December, 2031, following the expiration of the last patent held for Enstilar. This includes the possibility of a Para IV filing, which allows generic manufacturers to challenge the validity of branded drug patents.
Enstilar contains active ingredients Betamethasone Dipropionate and Calcipotriene, which work together to provide relief from plaque psoriasis. Betamethasone Dipropionate is a corticosteroid that reduces itching, redness, and swelling associated with various skin conditions. Calcipotriene is a form of vitamin D that helps to slow the rapid growth of skin cells associated with psoriasis.
Enstilar holds 10 patents, none of which have expired. The patents protect the pharmaceutical spray composition that includes a vitamin D analogue, Calcipotriene, and a corticosteroid, Betamethasone Dipropionate. The last of these Enstilar patents is set to expire on 10 December, 2031. For more on Enstilar generic release and patent details, continue reading below. Below are the details of the patent.